Proactive Investors - Run By Investors For Investors

Rhinomed Limited in halt on European sales of snoring product

Rhinomed Limited in halt on European sales of snoring product

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to European sales of its Mute over-the-counter snoring product.

The halt will last until the earlier of the announcement being made or the start of trade on Monday, 18th May 2015.

In April, the company expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to include Mute.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 15 2015

Related Articles

scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use